New hope for rare fever disorder: drug targets stubborn cases
NCT ID NCT06666335
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether anakinra (Kineret), a daily injection, can reduce monthly attacks in Chinese patients with Familial Mediterranean Fever (FMF) who do not respond to standard colchicine treatment. Three patients aged 2 years and older will receive anakinra for 6 months, with researchers tracking the number of fever and pain episodes. The goal is to see if this drug can safely control the disease in this hard-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anakinra (Kineret)
What this could lead to
If successful, anakinra could offer a new treatment option for Chinese patients with colchicine-resistant FMF, reducing painful attacks.
What could go wrong
This is a very small study (only 3 patients), so results may not apply broadly. Anakinra is already approved for other conditions, but its safety and efficacy in this specific population are still being confirmed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL MEDITERRANEAN FEVER (FMF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.